GDC-0994 potently inhibits phospho-p90RSK in tumor cells. GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. GDC-0994 subsequently prevents ERK-dependent tumor cell proliferation and survival.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Related ERK Products|
XMD8-92 is a potent and selective BMK1/ERK5 inhibitor with Kd of 80 nM.
VRT752271 (BVD-523, Ulixertinib) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
DEL-22379 is a water-soluble ERK dimerization inhibitor with IC50 of ∼0.5 μM.
XMD17-109 is a novel, specific inhibitor of ERK-5 with an EC50 value of 4.2 μM in HEK293 cells.
FR 180204 is an ATP-competitive, selective ERK inhibitor with Ki of 0.31 μM and 0.14 μM for ERK1 And ERK2, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.